Infectious disease
The U.S. Food and Drug Administration (FDA), a day after a positive advisory committee recommendation, granted an Emergency Use Authorization (EUA) to Pfizer and BioNTech for their COVID-19 vaccine. Dosing is expected to begin in days.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
All eyes on the FDA as they review a COVID-19 vaccine, FDA approval of an Emergency Use Authorization to LabCorp’s home test kit for COVID-19, the first testing device that does not require a prescription and more news.
Viruses mutate, and SARS-CoV-2, the virus that causes COVID-19, is not different. Luckily, it appears to mutate relatively slowly. Meanwhile, researchers are beginning to get a grip on the virus’s evolution.
Aridis’ COVID-19 therapy is particularly exciting. AR-711 is an inhaled, self-administered, at-home treatment for mild-to-moderate SARS-CoV-2 infections.
Documents related to the COVID-19 vaccine developed by Pfizer and BioNTech that were in possession of the European Medicines Agency have been accessed by hackers.
Vaccines are on the cusp of being authorized for use against COVID-19, but there is still a significant need for other therapeutics that will help patients who contract the virus fight off the devastating effects of the disease.
The COVID-19 vaccine under development by China’s Sinopharm is showing efficacy of 86%, health authorities from the United Arab Emirates reported this morning.
UK regulators stated today that they have received two reports of potential allergic reactions linked to the COVID-19 vaccine from Pfizer and BioNTech.
Although vaccines will be available pending approval, there are questions as to how many people will quickly receive the vaccine and when more will be available.
PRESS RELEASES